Pharmaceutical Business Review
Anonymous User | Login

Novartis' Tasigna Positive In Treating Chronic Myeloid Leukemia

Published: 05-Jun-2009

Research compared Tasigna against Glivec (imatinib) data

Novartis has announced positive results for Tasigna (nilotinib), for treating newly diagnosed chronic myeloid leukemia (CML). The research compared Tasigna against historical Glivec (imatinib) data in the treatment of patients with Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML).

Findings were presented at the 14th Congress of the European Hematology Association (EHA) in Berlin, Germany.

Phase II data demonstrates that Tasigna rapidly removes detectable cancer cells in 96% of patients in 12 months.

At 12 months, Tasigna also achieves a rapid and deep reduction of the abnormal protein that causes a life-threatening type of leukemia in majority of patients, as compared to historical Glivec data.

The company expects to complete the phase-III head-to-head registration trial evaluating Tasigna vs. Glivec in newly diagnosed patients in early 2010.

Share

Mail sent successfully

Tell your friend about this article


Please enter a valid email address

Please enter your name

Please enter the mail body


Your Name: *
Your Email: *
Friend's Email: *
Email Body: *
 

Suppliers To This Sector

Browse A-Z

# A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

ADAPT Localization

The Translation and Localization Specialists ...

Adis

Independently Evaluated Drug Information ...

Almac

Drug Development Solutions ...

Altiora

To Strive for the Highest ...

Anoto

Providing Unique Technology for Digital Pen and Paper ...

Aptuit

Drug Discovery and Development ...

White Papers

Browse A-Z

# A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

CaseBase Management

BaseCon was established in 1999 to support the pharmaceutical sector with innovative IT so ...

SafetyBase Interchange

BaseCon was established in 1999 to support the pharmaceutical sector with innovative IT so ...

ClinicalBase Trial

BaseCon was established in 1999 to support the pharmaceutical sector with innovative IT so ...

Reliable Prediction of White Plasma Levels

Our kinetics & metabolism experts can help you select and further develop your candidate d ...

Kinetics and Metabolism

Our kinetics & metabolism experts can help you select and further develop your candidate d ...

Drug Safety Evaluation

Our kinetics & metabolism experts can help you select and further develop your candidate d ...

Related Companies

GlaxoSmithKline plc

GlaxoSmithKline plc (GSK) is a is a United Kingdom-based pharmaceutical, biological, a ...

Merck KGaA

Merck KGaA (Merck) is a Germany-based company engaged in the manufacturing and distribu ...

Wyeth

Wyeth is engaged in developing and providing pharmaceuticals and healthcare products fo ...

Bristol-Myers Squibb Company

Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manuf ...

Johnson & Johnson

Johnson & Johnson (J&J) is engaged in the manufacture and sales of broad range of healt ...

Suppliers Product News

Almac Completes Phase One of Its Expansion Plan to Pharma Services Facilities

New $15m facility will "meet growing business need for its integrated product development and commercial services."

Organisations Throwing Mobile Technology at Problems With Little Consideration of Actual User and Business Needs, Quocirca

Survey reveals detrimental impact on organisational effectiveness and IT expenditure in healthcare and finance across the UK, France, Germany and the US.

Digital Pen and Paper Technology Helps Accelerate Clinical Trials

Digital pen and paper technology captures handwritten clinical data electronically, quickly and securely to save time and cost in drug discovery process.

Aptuit Outlines 2010 Business Priorities at 28th Annual J.P. Morgan Healthcare Conference

Aptuit, Inc., a contract development and manufacturing company, today will provide an update on 2010 business priorities and discuss its integrated service offerings at the 28th Annual J.P. Morgan Healthcare Conference in San Francisco.

Aptuit Publishes Study which Demonstrates the Value of Early Insights into the Characterisation of Drug Compounds

New research on the solid-state characterisation of finasteride clearly outlines a systematic approach to characterising and monitoring active pharmaceutical ingredients

Aptuit Launches Program to Accelerate Early Stage Drug Development

Aptuit INDiGO™ accelerates drug development from pre-clinical candidate selection to regulatory filing on a fixed timeline and price

Free Newsletter Sign-up

Sign up, and we will send you a free Pharmaceutical report on “ Combination Products – Evolution of the Medical Equipment Industry” from GlobalData worth $750

Please enter a valid email address